The amendment is a non-cash strategic alignment with no near-term revenue catalyst. Monitor for 2027 regulatory decisions in China and any subsequent milestone triggers. The equity stake provides optional upside but is highly speculative given Nicoya's private status and long timeline.
OPK drugs
OPK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $1.13entry
- T+1 · 7mo ago −2.65%α −2.87% · $1.10
- T+5 · 6mo ago −0.89%α −2.61% · $1.12
- T+20 · 6mo ago +26.55%α +21.58% · $1.43
- T+60 · 4mo ago +9.73%α +6.63% · $1.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in exchange for revised royalty/transfer pricing, while keeping the $115M milestone structure intact. The deal deepens strategic alignment for RAYALDEE commercialization in Greater China, where regulatory approvals are expected in 2027, but provides no immediate revenue or cash consideration.
Key Facts
- OPKO received a 15% equity stake in Nicoya via Series A-2 Preferred Shares in two tranches.
- Revised tiered royalty and transfer price schedule replaces prior terms; milestone payments up to $115M unchanged.
- RAYALDEE approved in Macau; regulatory approvals in China and related territories expected in 2027.
- No upfront cash payment or immediate revenue recognized from the amendment.
- OPKO's market cap is ~$843M; the equity stake value and milestone potential are unquantified in the release.
Financial Impact
Equity stake of 15% in Nicoya (private, unvalued); milestone potential up to $115M but contingent on future regulatory/sales events; no immediate cash flow impact.
Risk Factors
- Regulatory approvals in China may be delayed or denied, impairing milestone and royalty potential.
- Equity stake in private Nicoya is illiquid and may never generate realized value.
- RAYALDEE faces competition from existing vitamin D therapies and SHPT treatments in China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284852 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Viewing Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers